US Patent 8008452 Phosphorylated Ndr kinase
Patent 8008452 was granted and assigned to Novartis on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+341 characters)
Article
Patent abstract
The present invention relates to the phosphorylated form of nuclear serine/threonine protein kinase, designated nuclear, Dbf2-related kinase (Ndr), and provides assays and materials for identifying modulators thereof. The invention relates to the fields of molecular biology, chemistry, pharmacology, and screening technology.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08008452 Phosphorylated Ndr kinase US Patent 8008452 Phosphorylated Ndr kinase
Infobox
Patent Number
0800845200
Patent Number
800845200
Edits on 24 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080084520
Date of Patent
August 30, 2011
0Patent Application Number
105359200
Date Filed
November 25, 2003
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080084520
Date of Patent
August 30, 2011
0Patent Application Number
105359200
Date Filed
November 25, 2003
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08008452 Phosphorylated Ndr kinase
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08008452
Date of patent
August 30, 2011
Patent application number
10535920
Date Filed
November 25, 2003
Patent primary examiner
Find more entities like US Patent 8008452 Phosphorylated Ndr kinase
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
